Genetic variants in IL-33/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population

Wei, Zhongheng; Li, Yueyong; Huang, Shiqing; Tan, Zhiyuan

doi:10.1016/j.cyto.2018.03.036

Cited by 21 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These have been linked to autoimmune diseases such as multiple sclerosis and type I diabetes (193) but not to ALS (194). However, it would seem likely that genetic variation in immune genes could influence the immune abnormalities described above, For example, polymorphisms in cytokine genes can influence the levels of cytokines such as IL-6, (195) and TNFα (196) and the IL33/ST2 pathway (197).…”

Section: Immunogenetics Of Alsmentioning

confidence: 99%

The Peripheral Immune System and Amyotrophic Lateral Sclerosis

et al. 2020

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease that is defined by loss of upper and lower motor neurons, associated with accumulation of protein aggregates in cells. There is also pathology in extra-motor areas of the brain, Possible causes of cell death include failure to deal with the aggregated proteins, glutamate toxicity and mitochondrial failure. ALS also involves abnormalities of metabolism and the immune system, including neuroinflammation in the brain and spinal cord. Strikingly, there are also abnormalities of the peripheral immune system, with alterations of T lymphocytes, monocytes, complement and cytokines in the peripheral blood of patients with ALS. The precise contribution of the peripheral immune system in ALS pathogenesis is an active area of research. Although some trials of immunomodulatory agents have been negative, there is strong preclinical evidence of benefit from immune modulation and further trials are currently underway. Here, we review the emerging evidence implicating peripheral immune alterations contributing to ALS, and their potential as future therapeutic targets for clinical intervention.

show abstract

Section: Immunogenetics Of Alsmentioning

confidence: 99%

The Peripheral Immune System and Amyotrophic Lateral Sclerosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In a recent study, genetic variants in the IL-33/ST2 pathway were analyzed to determine their association with susceptibility to HCC in a Chinese population [ 83 ]. Genotyping of the IL-33 rs7025417 and ST2 rs3821204 alleles showed that the ST2 rs3821204 CC genotype was associated with a significantly increased risk of HCC that was more evident in smokers and drinkers.…”

Section: The Role Of Il33/st2 In Tumorigenesismentioning

confidence: 99%

“…Genotyping of the IL-33 rs7025417 and ST2 rs3821204 alleles showed that the ST2 rs3821204 CC genotype was associated with a significantly increased risk of HCC that was more evident in smokers and drinkers. Higher plasma levels of ST2 mRNA and protein suggested an increased risk due to enhanced ST2 production at the transcriptional and translational levels [ 83 ].…”

Section: The Role Of Il33/st2 In Tumorigenesismentioning

confidence: 99%

The Role of IL-33/ST2 Pathway in Tumorigenesis

Larsen

Minaya

Vaish

et al. 2018

IJMS

View full text Add to dashboard Cite

Cancer is initiated by mutations in critical regulatory genes; however, its progression to malignancy is aided by non-neoplastic cells and molecules that create a permissive environment known as the tumor stroma or microenvironment (TME). Interleukin 33 (IL-33) is a dual function cytokine that also acts as a nuclear factor. IL-33 typically resides in the nucleus of the cells where it is expressed. However, upon tissue damage, necrosis, or injury, it is quickly released into extracellular space where it binds to its cognate receptor suppression of tumorigenicity 2 (ST2)L found on the membrane of target cells to potently activate a T Helper 2 (Th2) immune response, thus, it is classified as an alarmin. While its role in immunity and immune-related disorders has been extensively studied, its role in tumorigenesis is only beginning to be elucidated and has revealed opposing roles in tumor development. The IL-33/ST2 axis is emerging as a potent modulator of the TME. By recruiting a cohort of immune cells, it can remodel the TME to promote malignancy or impose tumor regression. Here, we review its multiple functions in various cancers to better understand its potential as a therapeutic target to block tumor progression or as adjuvant therapy to enhance the efficacy of anticancer immunotherapies.

show abstract

“…Следует заметить, что неприлизин разрушает ANP, BNP и CNP, но не разрушает NT-proBNP. Поэтому при применении ингибиторов неприлизина, которые входят в состав новой группы лекарственных препаратов АРНИ (препарат сакубитрил/валсартан) увеличиваются концентрации и эффекты ANP, BNP и CNP, тогда как концентрация NT-proBNP не растет вследствие ингибирования неприлизина и сохраняет свое значение как маркер терапевтической эффективности и прогноза [50]. Таким образом, НУП на сегодняшний день являются общепризнанными маркерами СН, их высокая ценность в определении прогноза и стратификации риска больных СН неоднократно доказана в многочисленных клинических исследованиях.…”

Section: таблица 1 критерии диагностики хснunclassified

“…Трансмембранная форма (ST2L) связывается со св оим природным лигандом, интерлейкином -33 (ИЛ-33) и образует комплекс ИЛ-33/ST2L [49]. Известно, что данный комплекс обладает протективным действием в отношении кардиомиоцитов, испытывающих механическое напряжение вследствие гемодинамической нагрузки, препятствует развитию гипертрофии миокарда и обладает антифибротическим эффектом, а также препятствует апоптозу, тем самым защищая клетку от гибели [49,50]. Растворимая форма обладает противоположным эффектом: циркулирующие в крови sST2 являются «ловушкой» для ИЛ-33, тем самым нивелируя защитные эффекты сигнальной системы ИЛ-33/ST2L, что приводит к гипертрофии и фиброзу миокарда, дилатации камер сердца и снижению контрактильной способности миокарда ЛЖ [49,50].…”

Section: растворимый St2 рецепторunclassified

Clinical Value of Blood Biomarkers in Patients With Chronic Heart Failure

et al. 2018

View full text Add to dashboard Cite

Biomarkers (various laboratory biochemical markers), such as natriuretic peptides (NP), soluble ST2 receptor, copeptin, galectin-3, are widely studied in patients with chronic heart failure (CHF). The European Society of Cardiology recommends the determination of blood NP level in suspicion of HF and its use as one of the mandatory diagnostic criteria for CHF with preserved and mid-range ejection fraction. Dynamics of NP concentration may be predictor of the effectiveness of the therapy and the necessity of the titration of the dose of HF drugs. Neprilyzin destroys NP, but does not destroy their precursors, including NT-proBNP. Therefore, it is necessary to use NT-proBNP as a marker of therapeutic efficacy and prognosis when using neprilysine inhibitors (sacubitril). ST2 is a protein receptor for interleukin-33 (IL-33). The transmembrane ST2 (ST2L) binds to IL-33 and forms the IL-33/ST2L complex, which has a cardioprotective effect, prevents the development of myocardial hypertrophy, fibrosis and apoptosis. The soluble ST2 receptor (sST2) is a “trap” for IL-33 and neutralizes the protective effects of the IL-33/ST2L complex, which leads to hypertrophy and fibrosis of the myocardium, dilatation of the chambers and reduction of the contractility of the heart. It can be considered as a marker of unfavorable prognosis in heart failure, but it is not specific. Copeptin is a part of the arginine-vasopressin, or antidiuretic hormone, precursor which plays an important role in the pathogenesis of CHF. Since arginine-vasopressin has a short half-life and is unstable outside the body, copeptin is being actively investigated. Its level increases during the CHF decompensation and relates with the functional class of CHF. A combined measurement of the concentration of copeptin and NP may improve the risk stratification in CHF patients. Galectin-3 is a peptide that stimulates the activation of fibroblasts and the development of fibrosis. It increases in CHF patients and is associated with the severity of the condition, systolic and diastolic LV dysfunction and prognosis. Currently, NP are the best biomarkers that can and should be used in routine clinical practice. To prove the need for widespread use of other biomarkers, additional research is needed.

show abstract

Genetic variants in IL-33/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population

Cited by 21 publications

References 49 publications

The Peripheral Immune System and Amyotrophic Lateral Sclerosis

The Peripheral Immune System and Amyotrophic Lateral Sclerosis

The Role of IL-33/ST2 Pathway in Tumorigenesis

Clinical Value of Blood Biomarkers in Patients With Chronic Heart Failure

Contact Info

Product

Resources

About